Quantitative analysis of cathepsin L mRNA and protein expression during oral cancer progression

• Published in: Oral oncology 2003-10, Vol.39 (7), p.638-647
• Main Authors: Macabeo-Ong, Maricris, Shiboski, Caroline H., Silverman, Sol, Ginzinger, David G., Dekker, Nusi, Wong, David T.W., Jordan, Richard C.K.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Biomarkers, Tumor - biosynthesis; Biomarkers, Tumor - genetics; Cancer; Carcinoma, Squamous Cell - metabolism; Cathepsin L; Cathepsins - biosynthesis; Cathepsins - genetics; Cysteine Endopeptidases; Disease Progression; Dysplasia; Female; Fixation; Formalin; Gene Expression; Humans; Immunoenzyme Techniques; Male; Middle Aged; Mouth Neoplasms - metabolism; Neoplasm Proteins - biosynthesis; Neoplasm Proteins - genetics; Oral; PCR; Pilot Projects; Precancerous Conditions - metabolism; Real-time; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger - genetics; RNA, Neoplasm - genetics
• ISSN: 1368-8375; 1879-0593
• DOI: 10.1016/S1368-8375(03)00034-4

Although an important risk factor for oral cancer is the presence of epithelial dysplasia, most of these lesions will not progress to malignancy. Presently, for the individual patient with dysplasia, there are few reliable markers that may indicate the likelihood of progression to oral cancer. Cathepsin L is a lysosomal protease that degrades extracellular matrix material. Because cathepsin L is frequently overexpressed in oral squamous cell carcinoma (SCC) we hypothesized that it is also overexpressed in oral premalignancy and that premalignant lesions that progressed to oral cancer expressed higher levels of cathepsin L than those premalignant lesions that did not. In this retrospective pilot study we examined changes in cathepsin L expression at the mRNA level using quantitative TaqMan RT-PCR and at the protein level by immunohistochemistry in 33 routinely processed oral dysplastic lesions and 14 SCCs obtained from 33 patients. Sixteen of the dysplastic lesions progressed to oral SCC and 17 did not after several years of follow-up. Cathepsin L mRNA was overexpressed in 16/33 (48%) dysplastic lesions and in 9/14 (64%) oral SCC. Cathepsin L protein was also overexpressed in a large proportion of dysplasias and cancers. Overexpression was independent of dysplasia grade and identified in both those patients who progressed to oral SCC and in those who did not. Levels of cathepsin L mRNA and protein did not differ significantly in the progressing versus non-progressing dysplasias ( P=0.27). However, cathepsin L mRNA and protein were significantly lower in the non-progressing dysplasias when compared to the oral cancers ( P=0.03) but not in the progressing dysplasias suggesting a trend for dysplasias with overexpressed cathepsin L to be more likely to progress to oral cancer.